Sysmex stock analysis
Sysmex (0YX) Stock Price & Analysis
0YX Stock Chart & Stats
- Day’s Range
- EUR 11.23 - EUR 11.23
- 52-Week Range
- EUR 6.51 - EUR 12.35
- Previous Close
- EUR 11.31
- Volume
- N/A
- Average Volume (3M)
- 41
- Market Cap
- EUR 7.11B
- Enterprise Value
- EUR 1.11T
- Total Cash (Recent Filing)
- EUR 120.64B
- Total Debt (Recent Filing)
- EUR 118.73B
- Price to Earnings (P/E)
- 37.3
- Beta
- 0.42
- Next Earnings
- Feb 11, 2027 (Est.)
- EPS Estimate
- 0.11
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.81%
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Model
The installed-base model can make revenue more durable than one-time equipment sales because routine testing requires repeat consumables and support. As placements expand across hospitals and laboratories, recurring demand can deepen customer relationships and provide a foundation for sustained revenue visibility.
Multi-Year Revenue Expansion
Strong multi-year revenue expansion indicates that Sysmex has continued to grow its commercial footprint and demand for diagnostic solutions. Maintaining solid profitability and gross margins alongside that growth supports reinvestment in products, market expansion, and service capabilities over the coming quarters.
Positive Cash Generation
Positive operating and free cash flow give Sysmex internal funding for research, product development, equipment support, and other strategic needs. The TTM rebound strengthens near-term financial capacity and reduces reliance on external financing while the company continues expanding its diagnostic platform base.
Bears Say
Margin Compression
Lower operating and net margins suggest that recent growth is producing less profit per unit of revenue than at earlier peaks. If this pressure persists, it could reduce internal funding for innovation and expansion, while making earnings more sensitive to mix, pricing, and cost developments.
Rising Leverage
Although the balance sheet remains generally healthy, higher debt-to-equity increases financial commitments and modestly reduces flexibility. Greater leverage can constrain future capital allocation, raise sensitivity to financing conditions, and leave less balance-sheet capacity available for investment or unexpected needs.
Inconsistent Cash Conversion
Uneven conversion of accounting profit into free cash flow makes the timing and reliability of internally generated funds less predictable. Working-capital or investment-related volatility may complicate planning and could limit the consistency with which Sysmex funds growth, returns capital, or reduces debt.
Sysmex News
0YX FAQ
What was Sysmex’s price range in the past 12 months?
What is Sysmex’s market cap?
When is Sysmex’s upcoming earnings report date?
How were Sysmex’s earnings last quarter?
Is Sysmex overvalued?
Does Sysmex pay dividends?
What is Sysmex’s EPS estimate?
How many shares outstanding does Sysmex have?
What happened to Sysmex’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sysmex?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Sysmex
Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968 (originally known as TOA Medical Electronics Co., Ltd. until its rebranding in October 1998), specializes in the development, manufacturing, and global distribution of advanced diagnostic instrumentation, chemical reagents, and associated software. Its comprehensive product portfolio addresses various diagnostic needs. In hematology, it offers instruments for both three-part and five-part white blood cell differentiation, alongside efficient transport systems designed for high-volume laboratory testing. For urinalysis, the company provides systems capable of analyzing urine formed sediment. Its offerings extend to automated immunochemistry systems, which are adept at performing assays with minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Sysmex also manufactures flow cytometers, crucial for the analysis involved in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core areas, the company is deeply involved in oncology diagnostics, developing systems for detecting cancer lymph node metastasis and cancer genome profiling, as well as offering cytogenetic testing and specialized lab assay services. Sysmex also contributes to digital medicine through the development and sale of software for diagnostic information systems, alongside the creation, operation, and maintenance of IT solutions, platforms, and applications in this field. Its activities further encompass the development and sale of nucleic acid analogs, the full lifecycle management (marketing, development, design, manufacture, sale, and after-sales support) of medical robots, and the distribution and post-sales support for medical devices and reagents used in biotechnology, medical technology, and molecular cell analysis. Sysmex serves a diverse client base, including national, public, and private hospitals, universities, research institutes, and other medical facilities. With a robust international presence, the company exports its products to approximately 190 countries worldwide. Demonstrating its commitment to innovation, Sysmex Corporation maintains a strategic alliance with QIAGEN N.V. for the collaborative development and commercialization of cancer companion diagnostics utilizing Plasma-Safe-SeqS technology.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Hisashi Ietsugu
- Employees
- 10,861
- Website
- www.sysmex.co.jp
- Address
- 1-5-1, Wakinohama-Kaigandori, Kobe, HY, 651-0073, JP
Sysmex (0YX) Earnings & Revenues
0YX Company Deck
0YX Earnings Call
Earnings Call SentimentNegative
The earnings call presented several notable challenges, including a significant revenue decline due to a system transition in Japan and the impact of China's medical cost control policies. However, there were positive developments such as the launch of new products and progress in Alzheimer's testing. Despite these positive aspects, the lowlights indicating declines in revenue and profit suggest a cautious outlook.
View all DE:0YX earnings summaries0YX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 5 | 3 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 11 | 0 | 1 |










